BeiGene, Ltd/$ONC

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About BeiGene, Ltd

Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.

Ticker

$ONC
Sector
Primary listing

Employees

11,000

Headquarters

Basel, Switzerland

BeiGene, Ltd Metrics

BasicAdvanced
$38B
-
-$1.66
0.21
-

Bulls say / Bears say

BeiGene turned GAAP profitable for the first time in Q1 2025, posting net income of $1.27 million versus a $251.15 million loss in Q1 2024, thanks to a 49% year-over-year revenue growth to $1.12 billion.
Global sales of Brukinsa jumped 62% year-over-year to $792 million in Q1 2025, with U.S. sales rising 60% to $563 million and the drug becoming the market leader for new CLL patient starts across all lines of therapy.
The EMA’s CHMP issued a positive opinion on March 31, 2025, recommending Tevimbra for first-line treatment of extensive-stage small cell lung cancer, expanding BeiGene’s solid tumor immunotherapy opportunities in Europe.
BeiGene’s Q1 2025 revenue of $1.12 billion missed consensus forecasts of $1.13 billion, causing shares to fall more than 5% in pre-market trading and underscoring how sensitive investors are to growth expectations.
Brukinsa made up about 73% of Q4 2024 revenue ($828 million out of $1.13 billion), concentrating BeiGene’s top-line performance around a single product that faces competitive threats and patent expiration risk.
BeiGene monetized as much as $950 million in future royalties from its small cell lung cancer drug Imdelltra in a deal with Royalty Pharma, signaling a reliance on non-dilutive financing that may come at the expense of future cash flows.
Data summarised monthly by Lightyear AI. Last updated on 3 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ONC

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs